Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm Phase 4 study of ocrelizumab in Chinese patients with relapsing multiple sclerosis or primary progressive multiple sclerosis
CTR20251827Phase 4Active
- Sponsor
- Roche
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ocrelizumab in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) (2 cohorts), sponsored by Roche. Primary endpoints: Annualized relapse rate and Pharmacodynamic characterization. Started Jul 2025; status: active.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on CTR20251827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251827.